BioArctic AB engages in the research and development of modifying treatments and diagnostics for neurodegenerative diseases. The company is headquartered in Stockholm, Stockholm and currently employs 122 full-time employees. The company went IPO on 2017-10-12. The firm focuses on the research and development of treatments, which aim at diseases that affect the central nervous system (CNS). Its therapeutic areas encompass neurodegenerative disorders, Alzheimer's disease, Parkinson's disease, complete spinal cord injury, as well as other CNS disorders. The firm owns a technology platform, which develops a range of therapeutic monoclonal antibodies. The firm's pipeline includes product candidates in various clinical phases, such as BAN2401, AE1501, BAN0805, imaging and biochemical biomarkers, BBB-technology and SC0806. The firm also operates through SpineMedical AB.
최신 재무제표(Form-10K)에 따르면, BioArctic AB (publ)의 총 자산은 $2,575이며, 순이익입니다.
BRCTF의 주요 재무 비율은 무엇인가요?
BioArctic AB (publ)의 유동비율은 4.23이고, 순이익률은 51.12, 주당 매출은 $22.52입니다.
BioArctic AB (publ)의 매출은 부문 또는 지역별로 어떻게 나뉘나요?
BioArctic AB (publ) 주요 수익원은 Innovative Biological Drugs이며, 최신 수익 발표에서 수익은 257,351,999입니다. 지역별로는 North America이 BioArctic AB (publ)의 주요 시장이며, 수익은 144,515,000입니다.
BioArctic AB (publ)은 수익성이 있나요?
예, 최신 재무제표에 따르면 BioArctic AB (publ)의 순이익은 $1,022입니다.